Evidence mapPaperPMID 39611817Full record

ArticleAmerican journal of physiology. Heart and circulatory physiology2025

Reduced cofilin activity as a mechanism contributing to endothelial cell stiffening in type 2 diabetes.

Gavin Power, Olubodun M Lateef, Francisco I Ramirez-Perez, Yoskaly Lazo-Fernandez, Marc A Augenreich, Larissa Ferreira-Santos, Rogerio N Soares, Juan D Gonzalez-Vallejo, Marianna Morales-Quinones, Charles E Norton and 3 more

Abstract read
In one paragraph

Article in American journal of physiology. Heart and circulatory physiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Beneficial vascular effects of oral phosphatidylserine supplementation in type 2 diabetes.Journal of applied physiology (Bethesda, Md. : 1985) · 2026
    Trial
  2. Guidelines for evaluating endothelial function in vascular tissue.American journal of physiology. Heart and circulatory physiology · 2026
    Review
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Gavin PowerNextGen Precision Health, University of Missouri, Columbia, Missouri, United States.ORCID 0000-0001-6147-8647
Olubodun M LateefNextGen Precision Health, University of Missouri, Columbia, Missouri, United States.ORCID 0000-0002-4207-3422
Francisco I Ramirez-PerezNextGen Precision Health, University of Missouri, Columbia, Missouri, United States.ORCID 0000-0003-4920-383X
Yoskaly Lazo-FernandezNextGen Precision Health, University of Missouri, Columbia, Missouri, United States.ORCID 0000-0001-5793-7652
Marc A AugenreichNextGen Precision Health, University of Missouri, Columbia, Missouri, United States.ORCID 0000-0002-0719-8799
Larissa Ferreira-SantosNextGen Precision Health, University of Missouri, Columbia, Missouri, United States.ORCID 0000-0001-5738-1623
Rogerio N SoaresCollege of Education, Wayne State University, Detroit, Michigan, United States.ORCID 0000-0002-9877-683X
Juan D Gonzalez-VallejoNextGen Precision Health, University of Missouri, Columbia, Missouri, United States.ORCID 0000-0002-4682-6030
Marianna Morales-QuinonesNextGen Precision Health, University of Missouri, Columbia, Missouri, United States.ORCID 0009-0003-1734-5267
Charles E NortonDepartment of Medical Pharmacology and Physiology, University of Missouri, Columbia, Missouri, United States.ORCID 0000-0001-9442-4039
Camila Manrique-AcevedoNextGen Precision Health, University of Missouri, Columbia, Missouri, United States.ORCID 0000-0001-9341-404X
Luis A Martinez-LemusNextGen Precision Health, University of Missouri, Columbia, Missouri, United States.ORCID 0000-0002-6559-5717
Jaume PadillaNextGen Precision Health, University of Missouri, Columbia, Missouri, United States.ORCID 0000-0002-7944-4936

Funding

Targeting ADAM17 activity for correction of vascular insulin resistance in type 2 diabetesR01HL151384 · UNIVERSITY OF MISSOURI-COLUMBIA · 2025 to 2025
$682k
Female sex protects vascular smooth muscle cells from mitochondrial depolarization to oxidative stressR01NS134690 · UNIVERSITY OF MISSOURI-COLUMBIA · 2025 to 2025
$346k
American Heart Association (AHA) 23PRE1020897American Heart Association (AHA) 24EIA12488820HHS | National Institutes of Health (NIH) R01HL137769HHS | National Institutes of Health (NIH) R01HL151384HHS | National Institutes of Health (NIH) R01HL153264HHS | National Institutes of Health (NIH) R01NS134690HHS | National Institutes of Health (NIH) R21DK116081NHLBI NIH HHS R01 HL137769NHLBI NIH HHS R01 HL151384NHLBI NIH HHS R01 HL153264NIDDK NIH HHS R21 DK116081NINDS NIH HHS R01 NS134690
6 · The paper itself

Abstract

An emerging instigator of endothelial dysfunction in type 2 diabetes (T2D) is the stiffening of the cell. Previous reports suggest that polymerization of filamentous actin (F-actin) is a potential mediator of endothelial stiffening. Actin polymerization is limited by active cofilin, an F-actin-severing protein that can be oxidized, leading to its inactivation and loss of severing capability. Yet, whether these mechanisms are implicated in endothelial stiffening in T2D remains unknown. Herein, we report that endothelial cells exposed to plasma from male and female subjects with T2D, and the aortic endothelium of diabetic male mice (

Indexed as

ActinsCofilin 1Diabetes Mellitus, Type 2Endothelial CellsHydrogen PeroxideLim KinasesOxidative StressActin Depolymerizing FactorsAgedAnimalsCells, CulturedFemaleHumansMaleMiceMice, Inbred C57BLActin Depolymerizing FactorsActinsCFL1 protein, humanCfl1 protein, mouseCofilin 1Hydrogen PeroxideLIMK1 protein, humanLim Kinasescofilinendothelial dysfunctionendothelial stiffeningF-actintype 2 diabetes

Identifiers

PMID39611817
PMCPMC12204071

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.